F-18 Meta-fluorobenzylguanidine PET Imaging of Myocardial Sympathetic Innervation

Overview

Journal J Nucl Cardiol

Specialty Cardiology & Vascular Diseases

Date 2022 Jan 7

PMID 34993893

Citations 3

Authors

Milan Grkovski

Pat B Zanzonico

Shakeel Modak

John L Humm

Jagat Narula

Neeta Pandit-Taskar

Affiliations

Soon will be listed here.

Abstract

Background: I-123 meta-iodobenzylguanidine (MIBG) imaging has long been employed to noninvasively assess the integrity of human norepinephrine transporter-1 and, hence, myocardial sympathetic innervation. Positron-emitting F-18 meta-fluorobenzylguanidine (MFBG) has recently been developed for potentially superior quantitative characterization. We assessed the feasibility of MFBG imaging of myocardial sympathetic innervation.

Methods: 16 patients were imaged with MFBG PET (30-minute dynamic imaging of chest, followed by 3 whole-body acquisitions between 30 minutes and 4-hour post-injection). Blood kinetics were assessed from multiple samples. Pharmacokinetic modeling with reversible 1- and 2-compartment models was performed. Kinetic rate constants were re-calculated from truncated datasets. All patients underwent concurrent MIBG SPECT.

Results: MFBG myocardial uptake was rapid and sustained; the mean standardized uptake value (SUV (mean ± standard deviation)) was 5.1 ± 2.2 and 3.4 ± 1.9 at 1 hour and 3-4-hour post-injection, respectively. The mean K and distribution volume (V) were 1.1 ± 0.6 mL/min/g and 34 ± 22 mL/cm, respectively. Both were reproducible when re-calculated from truncated 1-hour datasets (Intraclass Correlation Coefficient of 0.99 and 0.91, respectively). Spearman's ϱ = 0.86 between MFBG SUV and V and 0.80 between MFBG PET-derived V and MIBG SPECT-derived heart-to-mediastinum activity concentration ratio.

Conclusion: MFBG is a promising PET radiotracer for the assessment of myocardial sympathetic innervation.

Citing Articles

Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes.

Zohora F, Nazari M, Sinusas A Curr Cardiol Rep. 2025; 27(1):61.

PMID: 40009333 DOI: 10.1007/s11886-025-02197-9.

Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.

Higuchi T, Chen X, Werner R Theranostics. 2024; 14(8):3178-3192.

PMID: 38855189 PMC: 11155404. DOI: 10.7150/thno.96743.

Sympathetic Nervous System and Atherosclerosis.

Wang Y, Anesi J, Maier M, Myers M, Oqueli E, Sobey C Int J Mol Sci. 2023; 24(17).

PMID: 37685939 PMC: 10487841. DOI: 10.3390/ijms241713132.

Stellate Ganglia and Cardiac Sympathetic Overactivation in Heart Failure.

Li Y Int J Mol Sci. 2022; 23(21).

PMID: 36362099 PMC: 9653702. DOI: 10.3390/ijms232113311.

References

Hagelberg N, Aalto S, Kajander J, Oikonen V, Hinkka S, Nagren K . Alfentanil increases cortical dopamine D2/D3 receptor binding in healthy subjects. Pain. 2004; 109(1-2):86-93. DOI: 10.1016/j.pain.2004.01.013. View

Jacobson A, Senior R, Cerqueira M, Wong N, Thomas G, Lopez V . Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010; 55(20):2212-21. DOI: 10.1016/j.jacc.2010.01.014. View

Slomka P, Rubeaux M, Meunier L, Dey D, Lazewatsky J, Pan T . Dual-Gated Motion-Frozen Cardiac PET with Flurpiridaz F 18. J Nucl Med. 2015; 56(12):1876-81. DOI: 10.2967/jnumed.115.164285. View

Carrio I, Cowie M, Yamazaki J, Udelson J, Camici P . Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging. 2010; 3(1):92-100. DOI: 10.1016/j.jcmg.2009.07.014. View

Wacker C, Wiesmann F, Bock M, Jakob P, Sandstede J, Lehning A . Determination of regional blood volume and intra-extracapillary water exchange in human myocardium using Feruglose: First clinical results in patients with coronary artery disease. Magn Reson Med. 2002; 47(5):1013-6. DOI: 10.1002/mrm.10125. View

Wu J, Gallezot J, Lu Y, Ye Q, Liu H, Esserman D . Simplified Quantification and Acquisition Protocol for I-MIBG Dynamic SPECT. J Nucl Med. 2018; 59(10):1574-1580. DOI: 10.2967/jnumed.117.202143. View

Wakasugi S, Inoue M, Tazawa S . Assessment of adrenergic neuron function altered with progression of heart failure. J Nucl Med. 1995; 36(11):2069-74. View

Zelt J, Britt D, Mair B, Rotstein B, Quigley S, Walter O . Regional Distribution of Fluorine-18-Flubrobenguane and Carbon-11-Hydroxyephedrine for Cardiac PET Imaging of Sympathetic Innervation. JACC Cardiovasc Imaging. 2020; 14(7):1425-1436. DOI: 10.1016/j.jcmg.2020.09.026. View

Bengel F, Barthel P, Matsunari I, Schmidt G, Schwaiger M . Kinetics of 123I-MIBG after acute myocardial infarction and reperfusion therapy. J Nucl Med. 1999; 40(6):904-10. View

10.

Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S . A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013; 6(7):772-84. DOI: 10.1016/j.jcmg.2013.02.007. View

11.

Chen J, Folks R, Verdes L, Manatunga D, Jacobson A, Garcia E . Quantitative I-123 mIBG SPECT in differentiating abnormal and normal mIBG myocardial uptake. J Nucl Cardiol. 2011; 19(1):92-9. DOI: 10.1007/s12350-011-9438-0. View

12.

Hunter C, Klein R, Beanlands R, deKemp R . Patient motion effects on the quantification of regional myocardial blood flow with dynamic PET imaging. Med Phys. 2016; 43(4):1829. DOI: 10.1118/1.4943565. View

13.

Wang T, Wu K, Miner R, Renaud J, Beanlands R, deKemp R . Reproducible quantification of cardiac sympathetic innervation using graphical modeling of carbon-11-meta-hydroxyephedrine kinetics with dynamic PET-CT imaging. EJNMMI Res. 2018; 8(1):63. PMC: 6054601. DOI: 10.1186/s13550-018-0421-5. View

14.

Henderson E, Kahn J, Corbett J, Jansen D, Pippin J, Kulkarni P . Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988; 78(5 Pt 1):1192-9. DOI: 10.1161/01.cir.78.5.1192. View

15.

Tobes M, Jaques Jr S, Wieland D, Sisson J . Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985; 26(8):897-907. View

16.

Boutagy N, Sinusas A . Recent Advances and Clinical Applications of PET Cardiac Autonomic Nervous System Imaging. Curr Cardiol Rep. 2017; 19(4):33. PMC: 5505688. DOI: 10.1007/s11886-017-0843-0. View

17.

Zhang H, Huang R, Cheung N, Guo H, Zanzonico P, Thaler H . Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014; 20(8):2182-91. PMC: 4072734. DOI: 10.1158/1078-0432.CCR-13-1153. View

18.

Nakajo M, Shimabukuro K, Yoshimura H, YONEKURA R, Nakabeppu Y, Tanoue P . Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med. 1986; 27(1):84-9. View

19.

Zelt J, deKemp R, Rotstein B, Nair G, Narula J, Ahmadi A . Nuclear Imaging of the Cardiac Sympathetic Nervous System: A Disease-Specific Interpretation in Heart Failure. JACC Cardiovasc Imaging. 2019; 13(4):1036-1054. DOI: 10.1016/j.jcmg.2019.01.042. View

20.

Haider N, Baliga R, Chandrashekhar Y, Narula J . Adrenergic excess, hNET1 down-regulation, and compromised mIBG uptake in heart failure poverty in the presence of plenty. JACC Cardiovasc Imaging. 2010; 3(1):71-5. DOI: 10.1016/j.jcmg.2009.11.002. View